Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Neuroprotective Products Market by Type (Cholinesterase inhibitors, NMDA receptor antagonists, Others), By Application (Alzheimer’s disease, Multiple sclerosis, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Neuroprotective Products Market by Type (Cholinesterase inhibitors, NMDA receptor antagonists, Others), By Application (Alzheimer’s disease, Multiple sclerosis, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 131701 3300 Pharma & Healthcare 377 234 Pages 4.7 (35)
                                          

The global neuroprotective products market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of neurological disorders and growing geriatric population. The cholinesterase inhibitors segment accounted for the largest share in the global neuroprotective products market in 2018, followed by NMDA receptor antagonists segment. The application segment of Alzheimer's disease accounted for the largest share in the global neuroprotective products market in 2018, followed by multiple sclerosis. North America was estimated to account for the largest share in the global neuroprotective products market in 2018, followed by Europe and Asia Pacific respectively.

Some Of The Growth Factors Of This Market:

  1. Increasing awareness about the benefits of Neuroprotective Products among consumers will also fuel the growth of this market in the coming years.
  2. The rising geriatric population base across various countries is also expected to boost demand for these products in the near future due to their ability to improve cognitive function and reduce symptoms associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease .

Industry Growth Insights published a new data on “Neuroprotective Products Market”. The research report is titled “Neuroprotective Products Market research by Types (Cholinesterase inhibitors, NMDA receptor antagonists, Others), By Applications (Alzheimer's disease, Multiple sclerosis, Others), By Players/Companies Genervon Biopharmaceuticals (Canada), NeuroVive Pharmaceutical (Sweden), Ceregene (USA), BHRPharma (Thailand), Neuren Pharmaceuticals (Australia), Allon therapeutics (Canada), Bionure Inc. (USA)”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Neuroprotective Products Market Research Report

By Type

Cholinesterase inhibitors, NMDA receptor antagonists, Others

By Application

Alzheimer's disease, Multiple sclerosis, Others

By Companies

Genervon Biopharmaceuticals (Canada), NeuroVive Pharmaceutical (Sweden), Ceregene (USA), BHRPharma (Thailand), Neuren Pharmaceuticals (Australia), Allon therapeutics (Canada), Bionure Inc. (USA)

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

234

Number of Tables & Figures

164

Customization Available

Yes, the report can be customized as per your need.


Global Neuroprotective Products Industry Outlook


Global Neuroprotective Products Market Report Segments:

The global Neuroprotective Products market is segmented on the basis of:

Types

Cholinesterase inhibitors, NMDA receptor antagonists, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Alzheimer's disease, Multiple sclerosis, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Genervon Biopharmaceuticals (Canada)
  2. NeuroVive Pharmaceutical (Sweden)
  3. Ceregene (USA)
  4. BHRPharma (Thailand)
  5. Neuren Pharmaceuticals (Australia)
  6. Allon therapeutics (Canada)
  7. Bionure Inc. (USA)

Global Neuroprotective Products Market Overview


Highlights of The Neuroprotective Products Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Alpha Hydroxy Acid for Cosmetic Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Cholinesterase inhibitors
    2. NMDA receptor antagonists
    3. Others
  1. By Application:

    1. Alzheimer's disease
    2. Multiple sclerosis
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Neuroprotective Products Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Neuroprotective Products Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available
                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Neuroprotective Products Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Neuroprotective Products Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Neuroprotective Products Market - Supply Chain
   4.5. Global Neuroprotective Products Market Forecast
      4.5.1. Neuroprotective Products Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Neuroprotective Products Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Neuroprotective Products Market Absolute $ Opportunity

5. Global Neuroprotective Products Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Neuroprotective Products Market Size and Volume Forecast by Type
      5.3.1. Cholinesterase inhibitors
      5.3.2. NMDA receptor antagonists
      5.3.3. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Neuroprotective Products Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Neuroprotective Products Market Size and Volume Forecast by Application
      6.3.1. Alzheimer's disease
      6.3.2. Multiple sclerosis
      6.3.3. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Neuroprotective Products Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Neuroprotective Products Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Neuroprotective Products Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Neuroprotective Products Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Neuroprotective Products Demand Share Forecast, 2019-2029

9. North America Neuroprotective Products Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Neuroprotective Products Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Neuroprotective Products Market Size and Volume Forecast by Application
      9.4.1. Alzheimer's disease
      9.4.2. Multiple sclerosis
      9.4.3. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Neuroprotective Products Market Size and Volume Forecast by Type
      9.7.1. Cholinesterase inhibitors
      9.7.2. NMDA receptor antagonists
      9.7.3. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Neuroprotective Products Demand Share Forecast, 2019-2029

10. Latin America Neuroprotective Products Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Neuroprotective Products Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Neuroprotective Products Market Size and Volume Forecast by Application
      10.4.1. Alzheimer's disease
      10.4.2. Multiple sclerosis
      10.4.3. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Neuroprotective Products Market Size and Volume Forecast by Type
      10.7.1. Cholinesterase inhibitors
      10.7.2. NMDA receptor antagonists
      10.7.3. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Neuroprotective Products Demand Share Forecast, 2019-2029

11. Europe Neuroprotective Products Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Neuroprotective Products Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Neuroprotective Products Market Size and Volume Forecast by Application
      11.4.1. Alzheimer's disease
      11.4.2. Multiple sclerosis
      11.4.3. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Neuroprotective Products Market Size and Volume Forecast by Type
      11.7.1. Cholinesterase inhibitors
      11.7.2. NMDA receptor antagonists
      11.7.3. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Neuroprotective Products Demand Share, 2019-2029

12. Asia Pacific Neuroprotective Products Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Neuroprotective Products Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Neuroprotective Products Market Size and Volume Forecast by Application
      12.4.1. Alzheimer's disease
      12.4.2. Multiple sclerosis
      12.4.3. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Neuroprotective Products Market Size and Volume Forecast by Type
      12.7.1. Cholinesterase inhibitors
      12.7.2. NMDA receptor antagonists
      12.7.3. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Neuroprotective Products Demand Share, 2019-2029

13. Middle East & Africa Neuroprotective Products Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Neuroprotective Products Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Neuroprotective Products Market Size and Volume Forecast by Application
      13.4.1. Alzheimer's disease
      13.4.2. Multiple sclerosis
      13.4.3. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Neuroprotective Products Market Size and Volume Forecast by Type
      13.7.1. Cholinesterase inhibitors
      13.7.2. NMDA receptor antagonists
      13.7.3. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Neuroprotective Products Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Neuroprotective Products Market: Market Share Analysis
   14.2. Neuroprotective Products Distributors and Customers
   14.3. Neuroprotective Products Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Genervon Biopharmaceuticals (Canada)
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. NeuroVive Pharmaceutical (Sweden)
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Ceregene (USA)
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. BHRPharma (Thailand)
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Neuren Pharmaceuticals (Australia)
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Allon therapeutics (Canada)
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Bionure Inc. (USA)
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. COMPANY8
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. COMPANY9
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us